{'fraction_non_alphanumeric': 0.026151930261519303, 'fraction_numerical': 0.009962640099626401, 'mean_word_length': 5.380952380952381, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[99mTc-nanocolloid: clinical results of its use as a new inflammation marker].

Fifty scintigrams were performed on 45 patients using 99mTc-nanocolloid in order to test its affinity for inflammatory lesions; in these patients there was clinical and/or radiological suspicion of an inflammatory process. There was good correlation between the degree of uptake and the activity of the inflammatory process. Specificity is limited because of uptake in certain tumours (eg. sarcomas of the extremities), but difficulties in differential diagnosis are not expected to be serious. Judging by our experience, 99mTc-nanocolloid is a promising substance for the scintigraphic demonstration of inflammatory foci. The advantages of this industrially prepared tracer over In-leucocytes and Ga-citrate are discussed.